Physician profile
Julia Kang
NPI 1609329853
$71,414.54
in general payments reported to CMS, 2019-2025
23 companies · $22K in 2025
The $22K reported for 2025 was more than what 95% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $978 · 2023: $27K · 2024: $21K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Honoraria: $22K · Travel and Lodging: $8,162 · Food and Beverage: $5,220 · Consulting Fee: $4,250 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,175.00 |
| Honoraria | $22,487.50 |
| Travel and Lodging | $8,161.77 |
| Food and Beverage | $5,220.39 |
| Consulting Fee | $4,250.00 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41,777.69 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $27,127.24 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $414.92 | 2022-2025 | Hydrus Microstent, Tryptyr |
| Sight Sciences, INC. | $316.65 | 2022-2024 | Omni Surgical System |
| Genentech USA, INC. | $264.59 | 2024-2025 | Susvimo, Vabysmo |
| Abbvie INC. | $163.38 | 2022-2024 | |
| Oyster Point Pharma, INC. | $158.09 | 2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $147.61 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $140.01 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $137.30 | 2022-2024 | Xiidra, Miebo |
| Rxsight INC | $124.95 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $123.33 | 2025 | Tecnis Iol |
| Apellis Pharmaceuticals, INC. | $119.02 | 2023 | Syfovre |
| Sun Pharmaceutical Industries INC. | $99.85 | 2022-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $60.78 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $59.81 | 2023 | |
| Azurity Pharmaceuticals, INC. | $45.21 | 2025 | Edarbi |
| Lilly USA, LLC | $38.32 | 2025 | Mounjaro, Zepbound |
| Dompe US, INC. | $24.47 | 2022 | |
| Galderma Laboratories, L.P. | $20.87 | 2024 | |
| Vital Connect, INC | $17.84 | 2025 | Vitalpatch Rtm |
| Aerie Pharmaceuticals, INC. | $17.70 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.